Shield's Feraccru gets registration in Australia

Commercial-stage pharmaceutical company Shield Therapeutics said on Tuesday that Australia's Therapeutics Goods Administration (TGA) has registered ‘Feraccru’ in the country’s Register of Therapeutic Goods, to treat iron deficiency with or without anaemia in adults.

The AIM-traded firm said Feraccru was already approved in the UK, the European Union, Switzerland and the United States for the treatment of iron deficiency with or without anaemia in adults.

It said Norgine would lead all marketing activities in Australia.

“The Therapeutic Goods Administration is Australia's regulatory authority for medicinal products,” the Shield board clarified in its statement.

At 1449 GMT, shares in Shield Therapeutics were down 0.76% at 38.95p.